Kit For Tc 99M-Sestamibi No.1 (kit for prep Tc 99m/sestamibi combination no.1)

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

Urinary Alkalinizers/Dextroamphetamine Transdermal

SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction.

MECHANISM OF ACTION: Urinary alkalinizers decrease the renal elimination of dextroamphetamine.(1)

CLINICAL EFFECTS: Concurrent use of dextroamphetamine and urinary alkalinizers may result in increased dextroamphetamine levels and side effects.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Coadministration of dextroamphetamine with urinary alkalinizing agents should be avoided.(1)

DISCUSSION: Concurrent use of alkalinizing agents with dextroamphetamine decreases the renal elimination of dextroamphetamine. Co-administration of these should be avoided because of the potential of increased actions of dextroamphetamine.(1)

Moderate Interaction: Assess the risk to the patient and take action as needed.

Urinary Alkalinizers/Quinidine

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Quinidine elimination is impaired by urinary alkalinization.

CLINICAL EFFECTS: Potentiation of quinidine effects may be observed.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Monitoring quinidine levels and cardiac function may be indicated. The quinidine dose may need to be adjusted when a urinary alkalinizer is started or stopped.

DISCUSSION: Additional documentation is necessary to confirm this potential interaction.

Urinary Alkalinizers/Sympathomimetics

SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed.

MECHANISM OF ACTION: Unionized sympathomimetic amines will be reabsorbed into systemic circulation from the distal tubules of the kidneys.

CLINICAL EFFECTS: Enhanced sympathomimetic activity and increased risk of sympathomimetic toxicity.

PREDISPOSING FACTORS: None determined.

PATIENT MANAGEMENT: Watch patient for enhanced sympathomimetic side effects when urinary alkalinizers are concomitantly used. A lower dose of certain sympathomimetics may be required.

DISCUSSION: Signs and symptoms of sympathomimetic toxicity include euphoria, confusion, delirium, hallucinations and nervousness.

There is no enhanced messaging for this drug.

• Lactation

• Bronchospastic pulmonary disease
• Congenital heart disease
• Hypocalcemia
• Metabolic alkalosis
• Pulmonary hypertension

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

Less Frequent

• Chest pain
• Vomiting

Rare or Very Rare

• Anaphylaxis
• Angina
• Angioedema
• Cardiac arrhythmia
• Edema
• Hypotension
• Seizure disorder

More Frequent

• Dysgeusia

Less Frequent

• Parosmia

Rare or Very Rare

• Acute abdominal pain
• Arthralgia
• Bradycardia
• Dizziness
• Dyspnea
• Fatigue
• Fever
• Flushing
• General weakness
• Headache disorder
• Injection site sequelae
• Nausea
• Pruritus of skin
• Skin rash
• Syncope
• Urticaria
• Xerostomia

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.

No enhanced messaging available.